Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Could Smart Watches And Phone Apps Detect Alzheimer’s Years Before Symptoms Present?

Executive Summary

Investigational therapies are finally achieving some success in treating Alzheimer’s disease, but a cure is not yet in sight. Medtech now has a golden opportunity in pre-symptomatic detection, according to digital health tech research initiative, EDoN.

You may also be interested in...

Alzheimer's Is A Repeat Target For FDA Breakthrough Device Path

NeuroDiagnostics LLC said its investigational Alzheimer's disease test had been designated by US FDA as a Breakthrough Device. This is at least the third company to achieve that recognition for technology targeting Alzheimer's this year.

IQuity Lands NIH Grant To Help Identify Alzheimer's Early

The $320k grant will support research that builds on IQuity’s autoimmune diagnostic expertise and new data analytics platform. The company believes the emerging therapies for Alzheimer's will be most effective if they are used to treat the disease early in its progression.

Global Device Approvals, Weekly Snapshot: Transcranial Stimulator For Alzheimer's, And More

A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. Among the five added this week, Neuronix's NeuroAD Non Invasive Cortical Enhancer technology was approved in Australia for use in Alzheimer's patients, in combination with "tailored cognitive therapy."

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts